It’s a very exciting time to be part of the biopharmaceutical sector. The scientific innovation we are seeing, and helping to drive, is revolutionizing how certain diseases are diagnosed, treated and in some cases, cured. Precision medicine and breakthrough science including antibody-drug conjugates, immunotherapy and monoclonal antibodies are transforming how patients with chronic and fatal diseases are being treated around the world.
The unprecedented investments Canada has made and the initiatives it has taken in support of health research and innovation are poised to unleash the full potential of the Canadian research enterprise. We have all the ingredients to become a top-tier nation.
We need to ensure that we continue to develop a robust health research and health innovation ecosystem that will improve the health and wellbeing of all Canadians. To this end we ask that candidates advocate for the following:
Federal policy must recognize the interdependent and interconnected nature of the complete research and innovation enterprise. Its policymaking processes must evolve to reflect and support that ecosystem. A whole-of-government approach is essential to ensuring taxpayer-funded investments hit their targets.
Budget 2018 was a landmark reinvestment into Canadian research and innovation. But Canada remains significantly outpaced internationally and there is much more to do to catch up and lead. Canada must stay focused and continue to reinvest in the Tri-Council, support our next generation of scientists and fund the full costs of research.
We encourage government leaders and representatives to continue to promote research and innovation initiatives that address the needs and ambitions of those who have been historically underrepresented within and by it – Indigenous peoples, women, veterans and those of diverse abilities and gender, ethnic and cultural identities.
Canada must exhibit strong leadership and consistency with respect to its health and biosciences sector. It must create a regulatory regime that promotes rather than inhibits investment, understanding that such investment ultimately feeds back into the entire research and innovation ecosystem and creates a net benefit to patients, the health system, the knowledge workforce, and the social and economic wellbeing of all Canadians.
CHP Canada’s members have a long history of advancing healthcare by developing products that allow Canadians to take better care of themselves. We are approaching an exciting point, where research and technology advancements are optimising health systems featuring self-care as one of the most innovative approaches to improving health coverage for all. We are confident that we can work with government and other stakeholders to advance self-care and support our member companies in their meaningful work for the everyday and long-term health of Canadians and the sustainability of our health care system.
Karen Proud, President, CHP Canada
Canada continues to be without a nation-wide strategy to address the diabetes epidemic. The longer we delay implementing coordinated efforts with targeted outcomes, the more diabetes prevalence will increase and the more Canadians will experience its tragic complications. We urge all parties to support Diabetes 360˚ so Canada can be a world leader in the fight against this disease.
Dr. Jan Hux, President and CEO, Diabetes Canada
The member companies of Innovative Medicines Canada have a strong history of success in discovering, developing and delivering medicines and vaccines that Canadians need to live healthy and productive lives. We have, over time and as a country, prioritized innovative health research within the health care system, with the effect of creating an environment that allows our best and brightest to do their complex and important work. We want to work with all levels of government will continue to support life sciences research in Canada through effective and thoughtful public policy. This includes developing policies and programs that ensure Canadians have access to new medicines, when they need them.
Pamela Fralick, President, Innovative Medicines Canada
At AGE-WELL, our focus is on helping older adults stay healthy and independent for as long as possible, while assisting those living with impairment and disability. We believe that technology can help all of us to age well but it is not enough. We need meaningful and sustained multi-sectoral partnerships to make a difference in the lives of Canadians.
Dr. Alex Mihailidis, Scientific Co-Director and CEO, AGE-WELL
As Canada’s leading mental health research centre, CAMH aims to revolutionize the understanding mental illness. Through research, and continued investment in research, we want to do for mental illness what others have done for epilepsy, heart disease and cancer. We want to help people see mental health for what it really is—health.
Dr. Bruce Pollock, Vice President Research, CAMH
Evidence is the most powerful tool in advancing health care, and to spark change we must connect research and real-world impact. That’s why at CHÉOS, we produce the high-quality evidence needed to create better health outcomes for Canadians. We must continue to work together, asking the relevant questions to address current gaps in knowledge while training the next generation of health researchers to push innovation even further.
Dr. Aslam Anis, Director, Centre for Health Evaluation and Outcome Sciences (CHÉOS)
Federal investments in health research not only contribute to a healthy vibrant population, they are drivers of Canada’s economy, fueling innovation and commercialization from coast to coast. Today in Canada, we understand that a limited portion of all health research dollars are targeted towards advancing health outcomes for children and youth who may suffer from rare disease, pediatric cancers, neurodevelopmental disabilities, or childhood asthma. The Pediatric Chairs of Canada and Children’s Healthcare Canada believe that investments in children’s health and health research are urgently required to reverse alarming trends in the health and wellbeing of children and youth in Canada.
Emily Gruenwoldt, President & CEO, Children′s Healthcare Canada and Executive Director, Pediatric Chairs of Canada
It is with great pleasure that Concordia University is participating in Research Canada’s Your Candidates, Your Health initiative. As a next-generation university committed to innovation and excellence in health research, we share Research Canada’s core values about the importance of promoting health research in all areas.
Dr. Christophe Guy, Vice-President, Research and Graduate Studies, Concordia University
Merck Canada strongly believes that collaboration is the key to the future of innovation in the health sector. Industry and government have a shared responsibility to work together towards the common goal of building a robust healthcare environment that will provide meaningful benefit to Canadian patients.
Jennifer Chan, Vice-President, Policy and External Affairs, Merck Canada
We believe that every Canadian has a fundamental right to experience optimal health and well-being. The National Collaborating Centre for Methods and Tools works collaboratively with the public health sector in Canada to ensure the most effective and cost-efficient programs are implemented so that optimal health and well-being are realized for all.
Dr. Maureen Dobbins, Scientific Director, NCCMT
Roche continues to grow its footprint in Canada with the establishment of four global hubs at our Mississauga site. This expansion is a testament to our skilled and talented workforce and offers tremendous opportunity to solidify Canada’s reputation as a life sciences hub.
Mr. Ronnie Miller, President and CEO, Hoffmann-La Roche Ltd.
With more than $4 billion in annual export value from its Canadian facilities and a global reputation for quality and innovation, Bausch Health, Canada remains focused on the development, distribution, and manufacturing of pharmaceutical products and technologies for Canadians, right here in Canada. Having manufacturing infrastructure in Canada allows for effective local production, resulting in faster access for patients.
Richard Lajoie, President and General Manager, Canada, Bausch Health
Canadians affected by rare diseases, many of whom are coping with severely debilitating or life threatening conditions, face many barriers to taking advantage of treatments. Our members are working to change that. Through our efforts to research and develop new therapies for rare diseases and support positive policy change, our goal is to bring new treatment options to the rare disease community in Canada.
Bob McLay, Chair, RAREi
Canada is a nation of innovators. On a per capita basis, Canada boasts the fourth-largest science and technology workforce in the world—and nowhere is our heritage richer and our potential greater than in health research.
Dr. Ryan Wiley, President, Shift Health and Policy Advisor, Research Canada
Research represents hope for everyone who ever has faced, or ever will face, the prospect of a major illness. Our objective at the Lady Davis Institute, which we share with Research Canada, is to advance science in order to improve the quality of life and outcomes for patients. Our researchers and clinicians work in a continuous feedback loop to translate knowledge from the bench to the bedside and back in furtherance of those objectives.